Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: Drug, nutritional, and respiratory therapies (an evidence-based review): Report of the quality standards subcommittee of the American academy of neurology

Neurology

Volumn 73, Issue 15, 2009, Pages 1218-1226

  Miller, R G ^a   Jackson, C E ^b   Kasarskis, E J ^c   England, J D ^d   Forshew, D ^a   Johnston, W ^e   Kalra, S ^e   Katz, J S ^a   Mitsumoto, H ^f   Rosenfeld, J ^g   Shoesmith, C ^h   Strong, M J ^h   Woolley, S C ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e UNIVERSITY OF ALBERTA   (Canada)

^f NEUROLOGICAL INSTITUTE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CREATINE; LITHIUM CARBONATE; NUTRACEUTICAL; RILUZOLE; VITAMIN;

AERATION; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL TRIAL; DISEASE COURSE; ENTERIC FEEDING; EVIDENCE BASED PRACTICE; FATIGUE; FORCED EXPIRATORY VOLUME; HUMAN; INVASIVE PROCEDURE; LUNG FUNCTION TEST; NAUSEA; NON INVASIVE PROCEDURE; NUTRITION; NUTRITIONAL ASSESSMENT; PATIENT CARE; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY FAILURE; RESPIRATORY FUNCTION; SUPPLEMENTATION; SYSTEMATIC REVIEW; WEIGHT;

AMYOTROPHIC LATERAL SCLEROSIS; ENTERAL NUTRITION; EVIDENCE-BASED MEDICINE; HUMANS; LITHIUM CARBONATE; QUALITY OF LIFE; RESPIRATORY THERAPY; RILUZOLE;

EID: 70350149848     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181bc0141     Document Type: Article

References (40)

1. Miller RG, Rosenberg JA, Gelinas DF, et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology 1999;52:1311-1323.
2. Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neu-rol 2006;5:140-147.
3. Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1997;49:657-659.
4. Bensimon G, Lacomblez L, Delumeau JC, Bejuit R, Truffinet P, Meininger V. A study of riluzole in the treatment of advanced stage or elderly patients with amyotro-phic lateral sclerosis. J Neurol 2002;249:609-615.
5. Yanagisawa N, Tashiro K, Tohgi H, et al. Efficacy and safety of riluzole in patients with amyotrophic lateral sclerosis: double-blind placebo-controlled study in Japan. Igakuno Ayumi 1997;182:851-866.
6. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2007;CD001447.
7. Meininger V, Bensimon G, Bradley WR, et al. Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5:107-117.
8. Mitchell JD, O?Brien MR, Joshi M. Audit of outcomes in motor neuron disease (MND) patients treated with ri-luzole. Amyotroph Lateral Scler 2006;7:67-71.
9. Traynor BJ, Alexander M, Corr B, Frost E, Mahon L, Hardiman O. Riluzole and prognosis in ALS: Findings of the Irish ALS register over a five year study period (1996 - 2000). Amyotroph Lateral Scler Other Motor Neuron Disord 2001;2(suppl 2):43-44. Abstract.
10. Brooks BR, Belden DS, Roelke K, et al. Survival in non-riluzole treated amyotrophic lateral sclerosis (ALS): motor neuron disease (MND) patients with onset before and since 1996 is identical: a clinic-based epidemiological study. Amyotroph Lateral Scler Other Motor Neuron Dis-ord 2001;2:60-61. Abstract.
11. Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi A. The King?s Database 1999-2000: an analysis of the effect on survival of interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2001;2:43. Abstract.
12. Fornai F, Longone P, Cafaro L, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2008;105:2052-2057.
13. Loser C, Aschl G, Hebuterne X, et al. ESPEN guidelines on artificial enteral nutrition-percutaneous endoscopic gastrostomy (PEG). Clin Nutr 2005;24:848-861.
14. Kasarskis EJ, Scarlata D, Hill R, Fuller C, Stambler N, Cedarbaum JM. A retrospective study of percutaneous en-doscopic gastrostomy in ALS patients during the BDNF and CNTF trials. J Neurol Sci 1999;169:118-125.
15. Chio A, Cucatto A, Terreni A, et al. Percutaneous endo-scopic gastrostomy in amyotrophic lateral sclerosis: Effects on nutritional status and survival. Neurol 1998;50(suppl 4):AB30. Abstract.
16. Chio A, Finocchiaro E, Meineri P, Bottacchi E, Schiffer D. Safety and factors related to survival after percutaneous endoscopic gastrostomy in ALS: ALS Percutaneous Endo-scopic Gastrostomy Study Group. Neurology 1999;53: 1123-1125.
17. Del Piano M, Occhipinti P, Orsello M, Ballare M. Percutaneous endoscopic gastrostomy (PEG) reduces complications and improves survival in amyotrophic lateral sclerosis (ALS). Gastrointest Endosc 1999;49:AB192. Abstract.
18. Desport JC, Mabrouk T, Bouillet P, Perna A, Preux PM, Couratier P. Complications and survival following radio-logically and endoscopically-guided gastrostomy in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2005;6:88-93.
19. Desport JC, Preux PM, Truong CT, Courat L, Vallat JM, Couratier P. Nutritional assessment and survival in ALS patients. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:91-96.
20. Mazzini L, Corra T, Zaccala M, Mora G, Del Piano M, Galante M. Percutaneous endoscopic gastrostomy and en-teral nutrition in amyotrophic lateral sclerosis. J Neurol 1995;242:695-698.
21. Mitsumoto H, Davidson M, Moore D, et al. Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4:177-185.
22. Rozier A, Ruskone Fourmestraux A, Rosenbaum A, Delvigne JM, Besancon F, Meininger V. [Role of percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis] [in French]. Rev Neurol 1991;147:174-176.
23. Mathus-Vliegen LM, Louwerse LS, Merkus MP, Tytgat GN, Vianney de Jong JM. Percutaneous endoscopic gas-trostomy in patients with amyotrophic lateral sclerosis and impaired pulmonary function. Gastrointest Endosc 1994; 40:463-469.
24. Chio A, Mora G, Leone M, et al. Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology 2002;59:99-103. (Pubitemid 34742801)
25. Shaw AS, Ampong MA, Rio A, et al. Survival of patients with ALS following institution of enteral feeding is related to pre-procedure oximetry: a retrospective review of 98 patients in a single centre. Amyotroph Lateral Scler 2006;7:16-21.
26. Forbes RB, Colville S, Swingler RJ. Frequency, timing and outcome of gastrostomy tubes for amyotrophic lateral sclerosis/motor neurone disease: a record linkage study from the Scottish Motor Neurone Disease Register. J Neurol 2004;251:813-817.
27. Bradley WG, Anderson F, Gowda N, Miller RG. Changes in the management of ALS since the publication of the AAN ALS practice parameter 1999. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5:240-244.
28. Groeneveld GJ, Veldink JH, van der Tweel I, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 2003;53:437-445.
29. Shefner JM, Cudkowicz ME, Schoenfeld D, et al. A clinical trial of creatine in ALS. Neurology 2004;63:1656-1661.
30. Desnuelle C, Dib M, Garrel C, Favier A. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis: ALS Riluzole-Tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2001;2:9-18.
31. Graf M, Ecker D, Horowski R, et al. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm 2005;112:649-660.
32. Heffernan C, Jenkinson C, Holmes T, et al. Management of respiration in MND/ALS patients: an evidence based review. Amyotroph Lateral Scler 2006;7:5-15.
33. Lechtzin N, Rothstein J, Clawson L, Diette GB, Wiener CM. Amyotrophic lateral sclerosis: evaluation and treatment of respiratory impairment. Amyotroph Lateral Scler Other Motor Neuron Disord 2002;3:5-13. (Pubitemid 34705121)
34. Melo J, Homma A, Iturriaga E, et al. Pulmonary evaluation and prevalence of non-invasive ventilation in patients with amyotrophic lateral sclerosis: a multicenter survey and proposal of a pulmonary protocol. J Neurol Sci 1999;169: 114-117.
35. Czaplinski A, Yen AA, Appel SH. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry 2006;77:390-392.
36. Jackson CE, Rosenfeld J, Moore DH, et al. A preliminary evaluation of a prospective study of pulmonary function studies and symptoms of hypoventilation in ALS/MND patients. J Neurol Sci 2001;191:75-78.
37. Elman LB, Siderowf AD, McCluskey LF. Nocturnal oxime-try: utility in the respiratory management of amyotrophic lateral sclerosis. Am J Phys Med Rehabil 2003;82:866-870.
38. Velasco R, Salachas F, Munerati E, et al. [Nocturnal oxim-etry in patients with amyotrophic lateral sclerosis: role in predicting survival] [in French]. Rev Neurol 2002;158: 575-578.
39. Lechtzin N, Wiener CM, Shade DM, Clawson L, Di-ette GB. Spirometry in the supine position improves the detection of diaphragmatic weakness in patients with amyotrophic lateral sclerosis. Chest 2002;121:436-442.
40. Varrato J, Siderowf A, Damiano P, Gregory S, Feinberg D, McCluskey L. Postural change of forced vital capacity predicts some respiratory symptoms in ALS. Neurology 2001; 57:357-359.